Hearscape
← Organizations
Organization

Fennec Pharmaceuticals

Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.

All ProgramsTherapeuticsDevices
Open filtered programs
Programs
2
linked to organization
Strong Evidence
1
1 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
1 / 1
industry vs non-industry records
Competitive Density
6
Pipeline Velocity
50
Completion Signal
100

Programs by Stage

Phase 11
Marketed1

Trial / Program Status

Active1
Marketed1

Modality Mix

Small Molecule2

Indication Coverage

Cisplatin-Induced Hearing Loss2
Hearing Loss2
Ototoxicity1

Program Types

Therapeutic2

Population Tags

cisplatin-ototoxicity2
adult1
otoprotection1
pediatric1
pedmark1
testicular-cancer1

Strong-Evidence Records

1 records
PEDMARK by Fennec Pharmaceuticals
Strong evidence
Small MoleculeMarketedMarketed

Systemic sodium thiosulfate reduces cisplatin-associated ototoxicity by chemically inactivating reactive platinum species after chemotherapy.

Checked Records With Caveats

2 checked · 0 open checks
City of Hope Pedmark adult testicular-cancer otoprotection study
Details checked
Small MoleculePhase 1Active

Intravenous Pedmark/sodium thiosulfate administered 6 hours after cisplatin to reduce cisplatin-induced ototoxicity in adult men receiving cisplatin-based chemotherapy for metastatic testicular germ cell tumors.

Data checks: institution-led-study, active-recruiting